Skip to main content

CORRECTION article

Front. Immunol., 19 December 2024
Sec. Inflammation
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1538819

Corrigendum: Pyroglutamyl aminopeptidase 1 is a potential molecular target toward diagnosing and treating inflammation

This article is a correction to:

  1. Pyroglutamyl aminopeptidase 1 is a potential molecular target toward diagnosing and treating inflammation

    1. Read original article
Hongfei JiangHongfei Jiang1Qiuyu Gong*Qiuyu Gong2*Renshuai Zhang*Renshuai Zhang1*
  • 1The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China
  • 2Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

A Corrigendum on
Pyroglutamyl aminopeptidase 1 is a potential molecular target toward diagnosing and treating inflammation

By Jiang H, Gong Q and Zhang R (2023). Front. Immunol. 14:1301539. doi: 10.3389/fimmu.2023.1301539

In the published article, there was an error in the Funding statement. The Funding statement for the Natural Science Foundation of Shandong Province (ZR2021QH212) is wrong. The correct statement is “Shandong Postdoctoral Science Foundation (SDCX-ZG-202203015). The correct Funding statement appears below.

“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research received funding supporting from the Shandong Postdoctoral Science Foundation (SDCX-ZG-202203015) and the Key Research and Development Project of Shaanxi Province (2023-YBSF-292).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pyroglutamyl aminopeptidase 1 (PGP-1), inflammation, biomarker, anti-inflammatory therapy, cancer

Citation: Jiang H, Gong Q and Zhang R (2024) Corrigendum: Pyroglutamyl aminopeptidase 1 is a potential molecular target toward diagnosing and treating inflammation. Front. Immunol. 15:1538819. doi: 10.3389/fimmu.2024.1538819

Received: 03 December 2024; Accepted: 04 December 2024;
Published: 19 December 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Jiang, Gong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qiuyu Gong, Z29uZ3FpdXl1QHhqdHUuZWR1LmNu; Renshuai Zhang, emhhbmdyZW5zaHVhaUBxZHUuZWR1LmNu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.